Lani
01-22-2013, 07:30 AM
Stage IVs:
The Breast
Volume 22, Issue 1 , Pages 1-12, February 2013
Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
Dorte L. Nielsen, Iben Kümler, Jesper A.E. Palshof, Michael Andersson
Received 15 May 2012; received in revised form 10 July 2012; accepted 23 September 2012. published online 18 October 2012.
Abstract
Therapies targeting the human epidermal growth factor receptor (HER) 2 are effective in metastatic breast cancer (MBC).
We review the efficacy of HER2-directed therapies, focussing on monoclonal antibodies and tyrosine kinase inhibitors targeting HER2 that have been tested in phase II–III studies in MBC.
Trastuzumab is an important component of first-line treatment of HER2-positive MBC. New anti-HER2 drugs have the potential to change clinical practice. The potential role of the different drugs and regimens is yet to be determined. The response rate for trastuzumab-DM1 of 26–64% is comparable to those obtained for capecitabine plus lapatinib (48%), continuing trastuzumab in combination with capecitabine (48%), pertuzumab plus trastuzumab (24%), and neratinib (24%). Strategies combining multiple HER2-directed therapies might yield additive or synergistic effects and lead to improved outcome.
The future challenges include understanding HER2 functions, designing rational combinations and optimal selection of patients.
The Breast
Volume 22, Issue 1 , Pages 1-12, February 2013
Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
Dorte L. Nielsen, Iben Kümler, Jesper A.E. Palshof, Michael Andersson
Received 15 May 2012; received in revised form 10 July 2012; accepted 23 September 2012. published online 18 October 2012.
Abstract
Therapies targeting the human epidermal growth factor receptor (HER) 2 are effective in metastatic breast cancer (MBC).
We review the efficacy of HER2-directed therapies, focussing on monoclonal antibodies and tyrosine kinase inhibitors targeting HER2 that have been tested in phase II–III studies in MBC.
Trastuzumab is an important component of first-line treatment of HER2-positive MBC. New anti-HER2 drugs have the potential to change clinical practice. The potential role of the different drugs and regimens is yet to be determined. The response rate for trastuzumab-DM1 of 26–64% is comparable to those obtained for capecitabine plus lapatinib (48%), continuing trastuzumab in combination with capecitabine (48%), pertuzumab plus trastuzumab (24%), and neratinib (24%). Strategies combining multiple HER2-directed therapies might yield additive or synergistic effects and lead to improved outcome.
The future challenges include understanding HER2 functions, designing rational combinations and optimal selection of patients.